NDAINTRAVENOUSSOLUTION
Approved
May 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
POSLUMA (flotufolastat f-18) by Blue Earth Diagnostics is positron emitting activity [moa]. Approved for prostate cancer. First approved in 2023.
Drug data last refreshed 21h ago
Mechanism of Action
Positron Emitting Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications (1)
Clinical Trials (1)
Androgen-responsive POSLUMA-guided Intra-prostatic Boost
Started Mar 2026
23 enrolled
Intermediate Risk Prostate CancerHigh Risk Prostate CancerProstate Cancer
Company
Worked on POSLUMA at Blue Earth Diagnostics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.